Synthesis of N-Succinimidyl 4-[18F]Fluorobenzoate ([18F]SFB)

Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography

Volumn 1, Issue , 2012, Pages 81-85

  Shao, Xia ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Radiochemical purity, analyzed using HPLC system; Synthesis of 18F SFB; Synthesis of N Succinimidyl 4 18F fluorobenzoate ( 18F SFB)

Indexed keywords

EID: 84886162172     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118140345.ch9     Document Type: Chapter

References (25)

1. Wust F, Hultsch C, Bergmann R, Johannsen B, Henle T. Radiolabeling of isopeptide N-(rglutamyl)- L-lysine by conjugation with N-succinimidyl-4-[18F]fluorobenzoate. Appl Radiat Isot 2003;59:43-48.
2. Wester HJ, Hamacher K, Stocklin G. A comparative study of n. c. a. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996;23:365-372.
3. Vaidyanathan E, Bigner DD, Zalutsky MR. Fluorine-18 labeled monoclonal antibody fragments: a potential approach for combining radioimmunoscintigraphy and positron emission tomography. J Nucl Med 1992;33:1535-1541.
4. 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl Radiat Isot 2003;58:201-207.
5. 18F]SFB). Appl Radiat Isot 2005;63:329-332.
6. 18F]fluorobenzoate, an agent for labeling proteins and peptides with 18F. Nat Protoc 2006;1(4):1655-1661.
7. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 2001;28:929-938.
8. Tang G, Zeng W, Meixiang Y, Kabalka G. Facile synthesis of N-succinimidyl 4- [18F]fluorobenzoate ([18F]SFB) for protein labeling. J Labelled Comp Radiopharm 2008;51: 68-71.
9. 18F-label the vasoactive transmitter urotensin-II as a ligand for positron emission tomography. Nucl Med Biol 2008;35:725-731.
10. Glaser M, Årstad E, Luthra SK, Robins EG. Two-step radiosynthesis of [18F]N-succinimidyl- 4-fluorobenzoate ([18F]SFB). J Labelled Comp Radiopharm 2009;52:327-330.
11. 2O was purchased from ABX, Germany, or Medical Isotopes, USA, and used as received.
12. 18F]fluoride target.
13. GE Healthcare, USA.
14. QMA-Light Sep-Pak cartridges were purchased from Waters (part no. WAT023525) and conditioned with 10 mL ethanol, 10 mL water, 10 mL 0.5 M sodium bicarbonate, and a further 10 mL water before use.
15. Potassium carbonate was purchased from Aldrich (part no. 209619) and used as received. Sterile water was purchased from Hospira (part no. 0409-4887-50) and used as received.
16. Kryptofix-[2.2.2] was purchased from Acros (part no. 29195-0010) and used as received. Anhydrous acetonitrile was purchased from Acros (part no. 61096-1000) and used as received.
17. Trimethylbenzeneaminium triflate precursor was purchased from ABX, Germany (product no. 4391.0100).
18. Anhydrous DMSO was purchased from Acros (part no. 61042-10000) and used as received. We noticed a gradual decline in yield throughout the lifetime of a bottle of DMSO and stress the importance of using anhydrous solvents in this synthesis.
19. Tetrapropylammonium hydroxide was purchased from Sigma-Aldrich, Switzerland (part no. 254533), and used as received.
20. O-(N-Succinimidyl)-N,N,N ',N'-tetramethyluronium tetrafluoroborate was purchased from Sigma-Aldrich, USA (part no. 385530), and used as received.
21. Acetic acid was purchased from Sigma-Aldrich, USA (part no. 242853) and diluted to 1.5% (v/v) with water.
22. Waters C18 Plus Sep-Pak cartridges were purchased from Waters (part no. WAT020515) and conditioned with 10 mL ethanol and 10 mL water before use.
23. HPLC column was purchased from Merck, Germany (part no. 1021290001).
24. N-Succinimidyl 4-fluorobenzoate was purchased from ABX, Germany (product no. 4392.0100).
25. Capintec, Inc., USA.